Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States

To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.

Automated summary

The study suggests that universal HCV rescreening for pregnant women without evidence of HCV from prior pregnancies is cost-effective and should be recommended nationwide.